Pipeline | Skyhawk Therapeutics

top of page

Careers

Our Pipeline

INTERNAL PIPELINE

Skyhawk develops a broad portfolio of small molecule RNA-modifying drug candidates that have the potential to improve the lives of patients by directly addressing the causes of disease.

Our wholly-owned pipeline includes programs across neurodegenerative, oncology, neuromuscular, rare and other disease types. Many of our programs are against targets formerly considered “undruggable” for traditional protein-targeting mechanisms.

SKY-0515
(Neuro)

SKY-1200
(Heme cancer)

SKY-1300
(Neuro)

SKY-1400
(Solid Tumor Cancer)

SKY-1500
(Neuro)

SKY-1600
(Neuro)

SKY-1700
(Fibrosis)

PARTNERED PIPELINE

Our confidential partnered pipeline with BMS, Merck, Vertex, Sanofi and Genentech includes over a dozen programs across neurodegenerative, oncology, neuromuscular, rare and other disease types.

bottom of page